Each tablet contains 20 mg rosuvastatin.
Mechanism of action:
(Statirose) Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase.
(Statirose) Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL
(Statirose) Rosuvastatin inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
- Treatment of hypercholesterolemia.
- Prevention of Cardiovascular Events.
Treatment of hypercholesterolaemia:
The recommended start dose is 10-20 mg orally once daily.
Dose adjustment to the next dose level can be made after 4 weeks, if necessary.
Prevention of cardiovascular events:
in the cardiovascular events risk reduction study, the dose used was 20 mg daily.
Statirose may be given at any time of day, with or without food.
Statirose is contraindicated:
- In patients with hypersensitivity to rosuvastatin or to any of the excipients.
- In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal (ULN).
- In patients with severe renal impairment (creatinine clearance <30 ml/min).
- In patients with myopathy.
- In patients receiving concomitant cyclosporine.
- During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.
10 scored tablets/strip.